Cargando…
A case of pembrolizumab-induced severe DKA and hypothyroidism in a patient with metastatic melanoma
Immune checkpoint inhibitors (ICIs) have revolutionised cancer therapy and improved outcomes for patients with advanced disease. Pembrolizumab, a monoclonal antibody that acts as a programmed cell death 1 (PD-1(PDCD1)) inhibitor, has been approved for the treatment of advanced melanoma and other sol...
Autores principales: | Hakami, Osamah A, Ioana, Julia, Ahmad, Shahzad, Tun, Tommy Kyaw, Sreenan, Seamus, McDermott, John H |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bioscientifica Ltd
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6432978/ https://www.ncbi.nlm.nih.gov/pubmed/30836329 http://dx.doi.org/10.1530/EDM-18-0153 |
Ejemplares similares
-
Spurious HbA1c results in patients with diabetes treated with dapsone
por: Aljenaee, Khaled, et al.
Publicado: (2019) -
New onset autoimmune diabetes mellitus and hypothyroidism secondary to pembrolizumab in a patient with metastatic lung cancer
por: Cunha, Clara, et al.
Publicado: (2022) -
Central serous chorioretinopathy secondary to intramuscular testosterone therapy
por: Lockhart, M, et al.
Publicado: (2023) -
Pomalidomide-induced hypothyroidism
por: Ali, Sulaiman Haji, et al.
Publicado: (2017) -
Durvalumab-induced diabetic ketoacidosis followed by hypothyroidism
por: Patel, Shivani, et al.
Publicado: (2019)